(UroToday.com) In this presentation, Dr. Eleni Efstathiou, discussed two oral abstracts from the Presidential Symposium: 1) Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol (LBA4PR) and 2) A phase 3 trial with a 2×2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1 (LBA5PR). Dr. Efstathiou focused on how these studies address two major unmet needs in prostate cancer: 1) effective therapeutic strategies for localized high-risk disease and 2) the added value of combinatorial strategies.